findmyKOL

Donald Eagerton, MD

Basic profile

Carolina Urologic Research Center

ORCIDNone on fileNPI
RegionMyrtle Beach, SC · SoutheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Donald Eagerton is an Endocrinology/Metabolic physician affiliated with Carolina Urologic Research Center. OpenAlex indexes 14 publications with 2,749 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
14publications

Distinct works indexed by OpenAlex.

2,749citations

Total citations across indexed works.

8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
55companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

55 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

55 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    32.5%
    Iron, parenteral preparations32.5%
    Ferric carboxymaltose100%
    Part B, office-administered13 patients
    P2Y12 inhibitor0%
    Clopidogrel100%
    Part D<11 patients
  • Musculoskeletal

    31.4%
    Other drugs affecting bone structure and mineralization22.8%
    Romosozumab-aqqg100%
    Part B, office-administered27 patients
    RANK Ligand Inhibitor7.3%
    Denosumab100%
    Part B, office-administered59 patients

    + 2 more classes in this area

  • Cardiovascular

    25.5%
    Other lipid modifying agents22.2%
    Inclisiran100%Icosapent Ethyl0%
    Part D + Part B<11 patients
    Statin1.7%
    Atorvastatin Calcium44%Rosuvastatin Calcium38%Pravastatin Sodium10%Simvastatin8%
    Part D121 patients

    + 12 more classes in this area

Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”